REGENXBIO (NASDAQ:RGNX – Get Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They currently have a $36.00 price objective on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 410.64% from the stock’s previous close.
Other equities analysts have also recently issued reports about the stock. Morgan Stanley reaffirmed an “overweight” rating and issued a $22.00 target price on shares of REGENXBIO in a report on Friday, November 15th. StockNews.com upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, September 20th. Chardan Capital reiterated a “buy” rating and set a $52.00 target price on shares of REGENXBIO in a research report on Wednesday, November 20th. Raymond James reissued an “outperform” rating and issued a $18.00 price target on shares of REGENXBIO in a report on Thursday, October 10th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $35.00 price objective on shares of REGENXBIO in a report on Wednesday, December 11th. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, REGENXBIO presently has an average rating of “Moderate Buy” and an average price target of $35.27.
Get Our Latest Report on REGENXBIO
REGENXBIO Stock Performance
Institutional Investors Weigh In On REGENXBIO
Hedge funds and other institutional investors have recently modified their holdings of the company. GAMMA Investing LLC boosted its position in REGENXBIO by 273.1% during the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 2,510 shares during the last quarter. FMR LLC boosted its holdings in shares of REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,656 shares during the last quarter. nVerses Capital LLC increased its stake in REGENXBIO by 183.3% in the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 2,200 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in REGENXBIO by 64.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock worth $100,000 after buying an additional 3,720 shares during the last quarter. Finally, Arizona State Retirement System grew its holdings in REGENXBIO by 20.6% in the 2nd quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company’s stock valued at $137,000 after buying an additional 1,997 shares during the period. 88.08% of the stock is currently owned by hedge funds and other institutional investors.
About REGENXBIO
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Featured Stories
- Five stocks we like better than REGENXBIO
- What is Forex and How Does it Work?
- Everything You Need to Know About Palantir’s Stock Slide
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Why Nike Is on The Verge of a Massive Comeback Rally
- Canadian Penny Stocks: Can They Make You Rich?
- 3 Stocks With Strong Capital Returns and Insider Buying Signals
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.